Open AccessA randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients
Author(s) -
Remko van Leeuwen,
Christine Katlama,
Robert L. Murphy,
Kathleen Squires,
José M. Gatell,
Andrzéj Horban,
Bonaventura Clotet,
Schlomo Staszewski,
Arne van Eeden,
Nathan Clumeck,
Mauro Moroni,
Andrew T. Pavia,
Reinhold Schmidt,
Juan González-Lahoz,
Julio S. G. Montaner,
Francisco Antúnes,
Robert Gulick,
Dénes Bánhegyi,
Marc van der Valk,
Peter Reiss,
Liesbeth van Weert,
Frank van Leth,
Victoria A. Johnson,
JeanPierre Sommadossi,
Joep M. A. Lange
Publication year - 2003
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/00002030-200305020-00007
Subject(s) - nevirapine , indinavir , lamivudine , stavudine , regimen , medicine , didanosine , protease inhibitor (pharmacology) , gastroenterology , viral load , virology , immunology , human immunodeficiency virus (hiv) , virus , antiretroviral therapy , hepatitis b virus
To compare one protease inhibitor (PI)-based and two PI-sparing antiretroviral therapy regimens.